This is a major pipeline catalyst that could transform Telix's imaging franchise by opening a much larger addressable market in initial prostate cancer diagnosis. Traders should monitor for BiPASS top-line data readout and subsequent NDA submission, as positive results could drive significant revenue expansion beyond current staging indications.
Drug in focus
TLX drug pipeline →Gozellix
▲ Bullish Named in this 6-K- Impact
- Phase
- Approved (FDA, March 21, 2025 — NDA 219592, 505(b)(2))
- Time to market
- Already marketed — FDA approved March 21, 2025; US commercial launch announced June 2025
- Next catalyst
- None dated
What to watchGozellix is an already-approved, launched product, so there is no approval binary left to trade, the investor angle is commercial execution. Watch Telix's quarterly revenue disclosures (FY2026 guidance of ~US$950-970M plus US$40M Regeneron other income, Q2 2026 reported Aug 20, 2026) and any market-share data vs. Lantheus' PYLARIFY and Telix's own Illuccix, since Gozellix partly cannibalizes its sibling product. Bigger single-stock moves in TLX over the next year are more likely to come from the therapy pipeline (ProstACT Phase 3) than from this imaging agent.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 2 $11.45entry
- T+1 · 3mo ago +2.53%α +1.49% · $11.74
- T+5 · 2mo ago +3.93%α +4.89% · $11.90
- T+20 · 7w ago −4.19%α −3.86% · $10.97
- T+52 · todayOpen
- T+60 · in 10d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Telix Pharmaceuticals completed enrollment of 350 patients in the Phase 3 BiPASS study of Illuccix and Gozellix for prostate cancer imaging in the pre-biopsy setting. The company also aligned with the FDA on an NDA pathway that, if approved, would support new product reimbursement and broaden patient access. This is a significant clinical milestone that could expand Telix's addressable market substantially if the study meets its primary objectives.
Key Facts
- Completed enrollment of 350 patients in the Phase 3 BiPASS study
- Aligned with FDA on an NDA pathway for BiPASS that would support new product reimbursement
- BiPASS is the first registrational study of 68Ga-PSMA-PET imaging in the pre-biopsy setting
- Prior PRIMARY and PRIMARY2 studies demonstrated combining PSMA-PET with MRI can reduce unnecessary biopsies by almost 50%
- Globally, more than 3 million prostate biopsies are performed annually, with up to 75% found to be negative
Financial Impact
Potential to expand PSMA-PET imaging from current staging/re-staging use to a substantially larger pre-biopsy patient population, representing a new clinical application with a dedicated reimbursement pathway
Risk Factors
- BiPASS study may not meet its primary endpoints
- FDA may not approve the NDA even if endpoints are met
- Competing imaging modalities or diagnostic approaches could emerge
- Reimbursement may be less favorable than anticipated
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-059952 |
| Document: a20260902bipasscompletio.htm | 0001628280-26-059952 |
| Document: 0001628280-26-059952-index-headers.html | 0001628280-26-059952 |
| Document: 0001628280-26-059952-index.html | 0001628280-26-059952 |
| Document: 0001628280-26-059952.txt | 0001628280-26-059952 |
Track record
27 reports on TLX
9 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 18 of 20 went positive at some point.
Filters
- Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
- Oct 20, 202627d ago 6-K Neutral 4/10 No price data
- Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
- Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
- Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
- Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
- Sep 1, 202610w ago 6-K Bullish 7/10 Viewing Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
- Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers